Clinical Trials: SEARCH[Study] TILT[Study:StudyFirstPostDate] AREA[SponsorSearch] Merck Sharp Dohme Corp
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 … 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 Next Last
#
NCTID/Status
Study
Last Changed
1
NCT00651014
Terminated
Terminated
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
Conditions: Hypercholesterolemia; Atherosclerosis
Intervention: Ezetimibe, Placebo
Conditions: Hypercholesterolemia; Atherosclerosis
Intervention: Ezetimibe, Placebo
April 15, 2015
2
NCT00535405
Completed
Completed
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
Conditions: Hypercholesterolemia
Intervention: Atorvastatin 10 Mg, Ezetimibe 10 Mg/simvastatin 20 Mg, Atorvastatin 20 Mg, Ezetimibe 10 Mg/simvastatin 40 Mg, Atorvastatin 40 Mg
Conditions: Hypercholesterolemia
Intervention: Atorvastatin 10 Mg, Ezetimibe 10 Mg/simvastatin 20 Mg, Atorvastatin 20 Mg, Ezetimibe 10 Mg/simvastatin 40 Mg, Atorvastatin 40 Mg
March 17, 2017
3
NCT04193215
Not yet recruiting
Not yet recruiting
V114 and Acute Otitis Media (V114-032/PNEU-ERA)
Conditions: Acute Otitis Media (AOM)
Intervention: V114, Pediatric Vaccines
Conditions: Acute Otitis Media (AOM)
Intervention: V114, Pediatric Vaccines
December 9, 2019
4
NCT04193202
Not yet recruiting
Not yet recruiting
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)
Conditions: Cough
Intervention: Gefapixant, Placebo
Conditions: Cough
Intervention: Gefapixant, Placebo
December 9, 2019
5
NCT04193176
Not yet recruiting
Not yet recruiting
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
Conditions: Cough
Intervention: Gefapixant, Placebo
Conditions: Cough
Intervention: Gefapixant, Placebo
December 9, 2019
6
NCT04191135
Not yet recruiting
Not yet recruiting
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Conditions: Triple Negative Breast Neoplasms
Intervention: Pembrolizumab, Olaparib, Carboplatin, Gemcitabine
Conditions: Triple Negative Breast Neoplasms
Intervention: Pembrolizumab, Olaparib, Carboplatin, Gemcitabine
December 5, 2019
7
NCT04191096
Not yet recruiting
Not yet recruiting
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Intervention: Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Intervention: Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
December 5, 2019
8
NCT04168190
Not yet recruiting
Not yet recruiting
A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (pPCV) in Adults
Conditions: Pneumonia, Pneumococcal
Intervention: PPCV, Pneumovax™23
Conditions: Pneumonia, Pneumococcal
Intervention: PPCV, Pneumovax™23
November 18, 2019
9
NCT04165798
Not yet recruiting
Not yet recruiting
Umbrella Master Protocol: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYNOTE-U01)
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
November 13, 2019
10
NCT04165096
Not yet recruiting
Not yet recruiting
Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYNOTE-01C)
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Pembrolizumab, MK-5890
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Pembrolizumab, MK-5890
November 14, 2019
11
NCT04165083
Not yet recruiting
Not yet recruiting
Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B/KEYNOTE-01B)
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Pembrolizumab, MK-4830
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Pembrolizumab, MK-4830
November 14, 2019
12
NCT04165070
Not yet recruiting
Not yet recruiting
Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYNOTE-01A)
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, MK-7684
Conditions: Carcinoma, Non-Small-Cell Lung
Intervention: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, MK-7684
November 14, 2019
13
NCT04153565
Not yet recruiting
Not yet recruiting
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
Conditions: Mesothelioma
Intervention: Pembrolizumab, Pemetrexed, Cisplatin
Conditions: Mesothelioma
Intervention: Pembrolizumab, Pemetrexed, Cisplatin
November 25, 2019
14
NCT04152863
Not yet recruiting
Not yet recruiting
Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
Conditions: Advanced/Metastatic Melanoma
Intervention: V937 IV, V937 IT, Pembrolizumab
Conditions: Advanced/Metastatic Melanoma
Intervention: V937 IV, V937 IT, Pembrolizumab
December 6, 2019
15
NCT04135352
Recruiting
Recruiting
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
Conditions: Neoplasm Metastasis
Intervention: 200 Mg Of Pembrolizumab, V938
Conditions: Neoplasm Metastasis
Intervention: 200 Mg Of Pembrolizumab, V938
November 13, 2019
16
NCT04129398
Recruiting
Recruiting
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
Conditions: Cytomegalovirus Infection; Cytomegalovirus Disease
Intervention: Letermovir Tablet, Letermovir IV
Conditions: Cytomegalovirus Infection; Cytomegalovirus Disease
Intervention: Letermovir Tablet, Letermovir IV
December 3, 2019
17
NCT04123366
Recruiting
Recruiting
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Conditions: Solid Tumors
Intervention: Olaparib, Pembrolizumab
Conditions: Solid Tumors
Intervention: Olaparib, Pembrolizumab
December 4, 2019
18
NCT04086472
Recruiting
Recruiting
Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of MK-1654 in Healthy Participants (MK-1654-005)
Conditions: Respiratory Syncytial Viruses
Intervention: MK-1654, Placebo, RSV-A Memphis 37b
Conditions: Respiratory Syncytial Viruses
Intervention: MK-1654, Placebo, RSV-A Memphis 37b
November 19, 2019
19
NCT04054544
Not yet recruiting
Not yet recruiting
Gluten Challenge Study in Celiac Disease Participants (MK-0000-402)
Conditions: Celiac Disease
Intervention: Gluten Powder 4g
Conditions: Celiac Disease
Intervention: Gluten Powder 4g
November 20, 2019
20
NCT04054193
Recruiting
Recruiting
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Conditions: Chemotherapy-induced Nausea and Vomiting
Intervention: Fosaprepitant, 5-HT3 Antagonist, Dexamethasone
Conditions: Chemotherapy-induced Nausea and Vomiting
Intervention: Fosaprepitant, 5-HT3 Antagonist, Dexamethasone
December 5, 2019
21
NCT04031846
Recruiting
Recruiting
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
Conditions: Pneumococcal Infections
Intervention: Rotarix™, Infantrix™ Hexa, V114, Prevnar 13™
Conditions: Pneumococcal Infections
Intervention: Rotarix™, Infantrix™ Hexa, V114, Prevnar 13™
December 5, 2019
22
NCT04029480
Recruiting
Recruiting
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Conditions: Type 2 Diabetes Mellitus
Intervention: Ertugliflozin 5 Mg, Ertugliflozin 15 Mg, Placebo, Placebo, Insulin, Metformin
Conditions: Type 2 Diabetes Mellitus
Intervention: Ertugliflozin 5 Mg, Ertugliflozin 15 Mg, Placebo, Placebo, Insulin, Metformin
December 5, 2019
23
NCT04016714
Recruiting
Recruiting
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13®, Vaxelis™, M-M-R®II, Varivax®
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13®, Vaxelis™, M-M-R®II, Varivax®
November 17, 2019
24
NCT04003636
Recruiting
Recruiting
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Conditions: Biliary Tract Carcinoma
Intervention: Pembrolizumab, Gemcitabine, Cisplatin, Placebo
Conditions: Biliary Tract Carcinoma
Intervention: Pembrolizumab, Gemcitabine, Cisplatin, Placebo
December 5, 2019
25
NCT04003103
Recruiting
Recruiting
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
Conditions: HIV-1 Infection
Intervention: Islatravir, Placebo
Conditions: HIV-1 Infection
Intervention: Islatravir, Placebo
December 4, 2019
26
NCT03998254
Recruiting
Recruiting
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
Conditions: Papillomavirus Infections
Intervention: V503, Gardasil
Conditions: Papillomavirus Infections
Intervention: V503, Gardasil
October 18, 2019
27
NCT03976375
Recruiting
Recruiting
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Conditions: Metastatic Non-Small Cell Lung Cancer
Intervention: Pembrolizumab, Lenvatinib, Docetaxel
Conditions: Metastatic Non-Small Cell Lung Cancer
Intervention: Pembrolizumab, Lenvatinib, Docetaxel
December 4, 2019
28
NCT03976362
Recruiting
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
Conditions: Carcinoma, Squamous Cell, Non-small-cell Lung
Intervention: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
Conditions: Carcinoma, Squamous Cell, Non-small-cell Lung
Intervention: Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Olaparib, Placebo
December 4, 2019
29
NCT03976323
Recruiting
Recruiting
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Conditions: Carcinoma, Non-squamous Non-small-cell Lung
Intervention: Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
Conditions: Carcinoma, Non-squamous Non-small-cell Lung
Intervention: Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
December 4, 2019
30
NCT03969901
Recruiting
Recruiting
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Conditions: Suspected or Documented Gram-negative Bacterial Infection
Intervention: IMI/REL, Active Control
Conditions: Suspected or Documented Gram-negative Bacterial Infection
Intervention: IMI/REL, Active Control
December 4, 2019
31
NCT03950856
Active, not recruiting
Active, not recruiting
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020/PNEU-TRUE)
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13®
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13®
October 10, 2019
32
NCT03950674
Active, not recruiting
Active, not recruiting
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
Conditions: Non-Small-Cell Lung Carcinoma
Intervention: Pembrolizumab 200 Mg, Cisplatin, Carboplatin, Pemetrexed, Folic Acid 350-1000 Μg, Vitamin B12 1000 Μg, Dexamethasone 4 Mg, Saline Solution
Conditions: Non-Small-Cell Lung Carcinoma
Intervention: Pembrolizumab 200 Mg, Cisplatin, Carboplatin, Pemetrexed, Folic Acid 350-1000 Μg, Vitamin B12 1000 Μg, Dexamethasone 4 Mg, Saline Solution
May 13, 2019
33
NCT03950622
Active, not recruiting
Active, not recruiting
Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13®
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13®
October 10, 2019
34
NCT03948763
Recruiting
Recruiting
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Conditions: Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Colorectal Neoplasms
Intervention: V941, Pembrolizumab
Conditions: Neoplasms; Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Colorectal Neoplasms
Intervention: V941, Pembrolizumab
October 18, 2019
35
NCT03940586
Recruiting
Recruiting
Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
Conditions: Cytomegalovirus (CMV) Infection
Intervention: Letermovir Oral Granules, Letermovir Tablet, Letermovir Intravenous
Conditions: Cytomegalovirus (CMV) Infection
Intervention: Letermovir Oral Granules, Letermovir Tablet, Letermovir Intravenous
December 4, 2019
36
NCT03933449
Active, not recruiting
Active, not recruiting
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
Conditions: Esophageal Carcinoma; Esophagogastric Junction Carcinoma
Intervention: Pembrolizumab, Paclitaxel, Docetaxel, Irinotecan
Conditions: Esophageal Carcinoma; Esophagogastric Junction Carcinoma
Intervention: Pembrolizumab, Paclitaxel, Docetaxel, Irinotecan
April 29, 2019
37
NCT03930615
Recruiting
Recruiting
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Conditions: Cytomegalovirus Infection
Intervention: Letermovir, Placebo
Conditions: Cytomegalovirus Infection
Intervention: Letermovir, Placebo
November 13, 2019
38
NCT03924895
Recruiting
Recruiting
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
Conditions: Urinary Bladder Cancer, Muscle-invasive
Intervention: Pembrolizumab, Surgery (radical Cystectomy (RC) Plus Pelvic Lymph Node Dissection [PLND])
Conditions: Urinary Bladder Cancer, Muscle-invasive
Intervention: Pembrolizumab, Surgery (radical Cystectomy (RC) Plus Pelvic Lymph Node Dissection [PLND])
December 5, 2019
39
NCT03924869
Recruiting
Recruiting
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
Conditions: Non-Small Cell Lung Cancer
Intervention: Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
Conditions: Non-Small Cell Lung Cancer
Intervention: Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
December 5, 2019
40
NCT03924856
Recruiting
Recruiting
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Conditions: Urinary Bladder Cancer, Muscle-invasive
Intervention: Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical Cystectomy (RC) Plus Pelvic Lymph Node Dissection [PLND]), Placebo
Conditions: Urinary Bladder Cancer, Muscle-invasive
Intervention: Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical Cystectomy (RC) Plus Pelvic Lymph Node Dissection [PLND]), Placebo
December 5, 2019
41
NCT03921424
Recruiting
Recruiting
Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13™, Pneumovax™23
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13™, Pneumovax™23
November 19, 2019
42
NCT03918278
Recruiting
Recruiting
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
Conditions: Neoplasms
Intervention: MK-0482, Pembrolizumab
Conditions: Neoplasms
Intervention: MK-0482, Pembrolizumab
December 5, 2019
43
NCT03909165
Recruiting
Recruiting
Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)
Conditions: Neuromuscular Blockade
Intervention: Sugammadex 2 Mg/kg, Sugammadex 4 Mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Conditions: Neuromuscular Blockade
Intervention: Sugammadex 2 Mg/kg, Sugammadex 4 Mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
December 5, 2019
44
NCT03903562
Active, not recruiting
Active, not recruiting
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
Conditions: Papillomavirus Infections
Intervention: V503
Conditions: Papillomavirus Infections
Intervention: V503
October 24, 2019
45
NCT03898180
Recruiting
Recruiting
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Conditions: Urothelial Carcinoma
Intervention: Pembrolizumab, Lenvatinib, Placebo For Lenvatinib
Conditions: Urothelial Carcinoma
Intervention: Pembrolizumab, Lenvatinib, Placebo For Lenvatinib
December 4, 2019
46
NCT03893448
Recruiting
Recruiting
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
Conditions: Pneumococcal Infections; Pneumococcal Vaccines
Intervention: V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R™, VARIVAX™, HIBERIX™
Conditions: Pneumococcal Infections; Pneumococcal Vaccines
Intervention: V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R™, VARIVAX™, HIBERIX™
December 5, 2019
47
NCT03885934
Recruiting
Recruiting
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (V114-024)
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13
Conditions: Pneumococcal Infections
Intervention: V114, Prevnar 13
December 5, 2019
48
NCT03885921
Completed
Completed
Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)
Conditions: Hypercholesterolemia
Intervention: Ezetimibe, Atorvastatin, Simvastatin
Conditions: Hypercholesterolemia
Intervention: Ezetimibe, Atorvastatin, Simvastatin
March 20, 2019
49
NCT03884452
Completed
Completed
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
Conditions: Familial Hypercholesterolemia
Intervention: Atorvastatin, Simvastatin, Ezetimibe, Placebo For Ezetimibe
Conditions: Familial Hypercholesterolemia
Intervention: Atorvastatin, Simvastatin, Ezetimibe, Placebo For Ezetimibe
June 11, 2019
50
NCT03884101
Recruiting
Recruiting
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Conditions: Endometrial Neoplasms
Intervention: Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin
Conditions: Endometrial Neoplasms
Intervention: Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin
December 4, 2019
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 … 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 Next Last
Last Updated
The last updated date is the most recent date when changes to a clinical trial were
submitted to ClinicalTrials.gov. There is often a delay of a few days before the
updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted
to ClinicalTrials.gov. There is often a delay of a few days before the
trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Safety Issue
If selected, restricts search results to those studies which have
an outcome measure designated as a safety issue. Note that this is a
poor estimate of the safety of a treatment or intervention, but it is
all we have now.
Funded By
Studies are supported by one or more organizations called sponsors.
Support includes contributions of facilities, expertise, and/or financial resources.
All sponsors in the database have been assigned one of the following organization types:
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Study Phase
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Age Group
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Gender
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility
name (such as the Mayo Clinic), enter it as a location term. Not all studies
include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency,
or organization sponsoring the trial. In addition, clinical trials assigns a
unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit.
Use this box to search for a trial by NCT identifier or any other study
identification numbers.
Examples:
Examples:
NCT00001789
97-h-0197
ia0006
actg 076
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is
conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are
conducting or otherwise supporting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Outcome Measures
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Outcome measures are used to evaluate trial results. For example, an obesity treatment
might be evaluated by a measure of weight loss after 6 months. Measures can also be used
to quantify side effects, such as number of myocardial infarctions,
number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Interventions
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Conditions
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Study Type
There are three types of studies available in ClinicalTrials.gov:
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Observational:
Expanded Access:
Studies where individuals are assigned to receive specific interventions.
Participants may receive diagnostic, therapeutic or other types of interventions.
Assignment of the intervention may or may not be random.
Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention.
Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals.
Participants may receive diagnostic, therapeutic, or other interventions, but the investigator
does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who
are failing on currently available treatments for their condition and also are unable to
participate in ongoing clinical trials. Expanded Access records are used to register all
types of non-protocol access to experimental treatments, including protocol exception,
single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Study Results
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Search Terms
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies.
These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Advanced Search:
Many searches are a single term and can be performed with a few words in the
search box. But, sometimes you need more control. Click on the Advanced Search tab
(if starting a new search) or Refine Search tab (if modifying an existing search)
to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Recruitment:
Interventions:
Outcomes Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
Country/State:
Location Terms:
Gender:
Age Group:
Phase:
Funded By:
Safety Issue:
First Received:
Last Updated:
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Performs a general search in all sections of the study record, including title,
description, conditions, interventions, locations, etc. Terms in this field are
searched the same as Basic Search.
Recruitment:
Limits search results to studies that are open or closed. New volunteers may be
able to participate in open studies, but not closed studies.
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Study Results:Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Values are color coded (as shown) in the search results.
Limits search results based on whether the study has results or not:
Study Type:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov.
Only a few studies have results available.Studies With Results, or
Studies Without Results
Limits search results to any of the following study types:
Conditions:
Interventional,
Observational, or
Expanded Access
Observational, or
Expanded Access
Performs a search on fields describing the diseases or conditions being studied.
Interventions:
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Sponsor/Collaborators:
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor (Lead):
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Study IDs:
Performs a search on fields listing ID numbers.
Country/State:
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state (e.g., United States, Alabama).
Location Terms:
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic).
Not all studies include this level of detail, but if they do, this will find them.
Gender:
Limits search results to those studies that accept female or male participants.
Age Group:
Limits search results to those studies that include at least one of the specified age
ranges. More than one age group can be selected.
Phase:
Limits search results to studies that are labeled with at least one of the specified
phases. More than one Phase can be selected.
Funded By:
Limits search results to studies that have at least one sponsor of the specified types.
More than one sponsor type can be selected.
Safety Issue:
Limits search results to studies that have at least one outcome measure designated as a safety issue.
First Received:
Limits search results to studies that were received by clinical trials within a
specified date range. The "From" or "To" field can be left blank.
Last Updated:
Limits search results to studies that were modified within a
specified date range. The "From" or "To" field can be left blank.
Refine Search:
Searches display a list of studies found (List Results tab). If you are not content with
the search results, click on the Refine Search tab at the top of the list to modify your
search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
When you are done making changes, click Search to display the new results.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
For example:
prostate cancer AND radiation
heart disease AND stroke AND California
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Aspirin OR ibuprofen
heart disease OR heart attack
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.